These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 4085218)

  • 1. Depletion of complement by light and porphyrin does not depend on sequential activation.
    Bauman N; Pease BS
    Complement; 1985; 2(2-3):127-32. PubMed ID: 4085218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Photodynamic action of uroporphyrin on the complement system in porphyria cutanea tarda.
    Meurer M; Schulte C; Weiler A; Goerz G
    Arch Dermatol Res; 1985; 277(4):293-8. PubMed ID: 3923948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complement-derived chemotactic activity is generated in human serum containing uroporphyrin after irradiation with 405 nm light.
    Lim HW; Perez HD; Goldstein IM; Gigli I
    J Clin Invest; 1981 Apr; 67(4):1072-7. PubMed ID: 7204567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complement activity in normal rabbit bronchoalveolar fluid. Description of an inhibitor of C3 activation.
    Giclas PC; King TE; Baker SL; Russo J; Henson PM
    Am Rev Respir Dis; 1987 Feb; 135(2):403-11. PubMed ID: 3643768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Humanized cobra venom factor: experimental therapeutics for targeted complement activation and complement depletion.
    Vogel CW; Fritzinger DC
    Curr Pharm Des; 2007; 13(28):2916-26. PubMed ID: 17979736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of aspirin on the complement system in vitro.
    Hänsch GM; Voigtländer V; Rother U
    Int Arch Allergy Appl Immunol; 1980; 61(2):150-8. PubMed ID: 7351347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of complement and polymorphonuclear cells in demethylchlortetracycline-induced phototoxicity in guinea pigs. Inhibition by decomplementation in vivo.
    Lim HW; Novotny H; Gigli I
    J Clin Invest; 1983 Oct; 72(4):1326-35. PubMed ID: 6415108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of complement in porphyrin-induced photosensitivity.
    Lim HW; Gigli I
    J Invest Dermatol; 1981 Jan; 76(1):4-9. PubMed ID: 7462666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complement cleavage products in the phototoxic reaction of porphyria cutanea tarda.
    Pigatto PD; Polenghi MM; Altomare GF; Giacchetti A; Cirillo R; Finzi AF
    Br J Dermatol; 1986 May; 114(5):567-73. PubMed ID: 3487340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The functional inhibition of activated C1 inhibitor in normal human serum causes spontaneous consumption of the complement components C2, C3, C4, and factor B.
    Gronski P; Bodenbender L; Kanzy EJ; Piepenbrock M; Seiler FR
    Immunobiology; 1986 Apr; 171(3):252-62. PubMed ID: 3011651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complement depletion with humanised cobra venom factor: efficacy in preclinical models of vascular diseases.
    Vogel CW; Fritzinger DC; Gorsuch WB; Stahl GL
    Thromb Haemost; 2015 Mar; 113(3):548-52. PubMed ID: 25031089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibitory effect of FUT-175 on complement activation and its application for glomerulonephritis with hypocomplementemia.
    Fujita Y; Inoue I; Inagi R; Miyata T; Shinzato T; Sugiyama S; Miyama A; Maeda K
    Nihon Jinzo Gakkai Shi; 1993 Apr; 35(4):393-7. PubMed ID: 8341019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyanate as an inactivator of complement proteins.
    Schultz DR; Arnold PI
    J Immunol; 1975 Dec; 115(6):1558-65. PubMed ID: 1184967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Control of C1 activation by nascent C3b and C4b: a mechanism of feedback inhibition.
    Ziccardi RJ
    J Immunol; 1986 May; 136(9):3378-83. PubMed ID: 3485688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional assay of C5-activating and nonactivating cobra venom factor preparations in the mouse system.
    Van den Berg CW; Aerts PC; Van Dijk H
    J Immunol Methods; 1990 Oct; 133(2):199-206. PubMed ID: 2230138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of complement in thrombogenesis. I. Complement-dependent coagulation in a model system.
    Abdulla YH; McFarlene E
    Atherosclerosis; 1977 Nov; 28(3):257-70. PubMed ID: 597343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complement and leukocyte independent proteinuria and eicosanoid synthesis in rat membranous nephropathy.
    Rahman MA; Liu CN; Dunn MJ; Emancipator SN
    Lab Invest; 1988 Oct; 59(4):477-83. PubMed ID: 3050273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complement and myoblast transfer therapy: donor myoblast survival is enhanced following depletion of host complement C3 using cobra venom factor, but not in the absence of C5.
    Hodgetts SI; Grounds MD
    Immunol Cell Biol; 2001 Jun; 79(3):231-9. PubMed ID: 11380675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heparin and derivatized heparin inhibit zymosan and cobra venom factor activation of complement in serum.
    Edens RE; Linhardt RJ; Bell CS; Weiler JM
    Immunopharmacology; 1994; 27(2):145-53. PubMed ID: 8014028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms of complement activation by crystalline cholesterol.
    Vogt W; von Zabern I; Damerau B; Hesse D; Lühmann B; Nolte R
    Mol Immunol; 1985 Feb; 22(2):101-6. PubMed ID: 3156272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.